TSVT

2seventy bio, Inc. [TSVT] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

TSVT Stock Summary

Top 10 Correlated Stocks

TSVT


In the News

02:48 10 Dec 2023 TSVT

Best Penny Stocks To Buy? 4 To Watch With Big News This Week

Penny stocks, securities with share prices under $5, offer investors a chance at exponential returns with little upfront investment. However, investing wisely in penny stocks requires research as their prices fluctuate wildly around key events.

12:35 10 Dec 2023 TSVT

Bristol-Myers Squibb, 2seventy Bio Shares Fall as FDA Delays Decision on Cancer Drug

Shares of Bristol-Myers Squibb (BMY) and partner 2seventy bio (TSVT) slumped after the two companies announced that the Food and Drug Administration (FDA) would not make a decision on expanded use for their blood cancer treatment, Abecma, next month as originally planned.

08:35 10 Dec 2023 TSVT

Bristol Myers Squibb, 2seventy bio shares fall as FDA delays action on cancer treatment

Shares of Bristol Myers Squibb Co. BMY and 2seventy bio Inc. TSVT fell premarket on Monday after the companies said the U.S. Food and Drug Administration would miss its target date for potential approval of earlier use of a cancer therapy.

11:17 10 Dec 2023 TSVT

2seventy bio, Inc. (TSVT) Loses -44.63% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

2seventy bio, Inc. (TSVT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

01:26 10 Dec 2023 TSVT

3 Biotech Stocks With Key Catalysts Coming in December

Some of the most exciting opportunities can be found in biotech stocks. In fact, find one with a powerful catalyst just around the corner, and you can make a good deal of money.

11:17 10 Dec 2023 TSVT

2seventy bio, Inc. (TSVT) Expected to Beat Earnings Estimates: Should You Buy?

2seventy bio, Inc. (TSVT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

10:00 10 Dec 2023 TSVT

Short squeeze alert for October 18th: 2 stocks that could soar

In stock trading, shorting is seen as a high-risk, high-reward strategy. This approach involves borrowing stocks, selling them, and betting on their price dropping to make a profit.

06:29 10 Dec 2023 TSVT

2 Growth Stocks That Could Rocket Higher Before the End of 2023

Upcoming announcements from the U.S. Food and Drug Administration could cause several biotech stocks to rocket higher. Alnylam is expecting a decision regarding a progressive heart condition that could lead to billions in additional annual sales.

01:31 10 Dec 2023 TSVT

2seventy bio (TSVT) to Cut Jobs & Expand JW Therapeutics Deal

2seventy bio (TSVT) undertakes a restructuring program and announces plans to reduce 40% of its workforce. The company also plans to expand its collaboration with JW Therapeutics.

07:40 10 Dec 2023 TSVT

2seventy bio to lay off 40% of workforce

2seventy bio said on Tuesday it plans to lay off about 40% of its workforce to lower costs and focus on the biotech firm's cancer cell therapy Abecma.

TSVT Financial details

Company Rating
Buy
Market Cap
156.91M
Income
-179.35M
Revenue
145.88M
Book val./share
5.99
Cash/share
4.9
Dividend
-
Dividend %
-
Employees
425
Optionable
No
Shortable
Yes
Earnings
14 Nov 2023
P/E
-0.88
Forward P/E
-1.85
PEG
-0
P/S
1.08
P/B
0.52
P/C
0.63
P/FCF
-0.9
Quick Ratio
3.97
Current Ratio
4.08
Debt / Equity
0.85
LT Debt / Equity
0.81
-
-
EPS (TTM)
-652.62
EPS next Y
-1.68
EPS next Q
-1.46
EPS this Y
-39.32%
EPS next Y
-99.74%
EPS next 5Y
-99.71%
EPS last 5Y
-3.63%
Revenue last 5Y
10.89%
Revenue Q/Q
-66.62%
EPS Q/Q
68.67%
-
-
-
-
SMA20
-7.14%
SMA50
-36.13%
SMA100
-79.21%
Inst Own
63.06%
Inst Trans
0.55%
ROA
-28%
ROE
-52%
ROC
-0.36%
Gross Margin
80%
Oper. Margin
-140%
Profit Margin
-123%
Payout
-
Shs Outstand
50.62M
Shs Float
47.05M
-
-
-
-
Target Price
26
52W Range
1.535-15.25
52W High
-79.33%
52W Low
+210%
RSI
67.36
Rel Volume
3.33
Avg Volume
1.92M
Volume
6.41M
Perf Week
61.46%
Perf Month
21.57%
Perf Quarter
-69.58%
Perf Half Y
-74.4%
-
-
-
-
Beta
1.127
-
-
Volatility
0.41%, 0.32%
Prev Close
16.98%
Price
3.1
Change
31.36%

TSVT Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
2.341.910.652.322.57
Net income per share
-8.58-13.88-5.93-11.75-7.13
Operating cash flow per share
-6.28-8.93-2.91-8.81-6.65
Free cash flow per share
-8.46-11.5-3.87-9.64-7.3
Cash per share
0-5.74-5.4811.287.47
Book value per share
01.883.215.318.71
Tangible book value per share
00.912.414.388.17
Share holders equity per share
01.883.215.318.71
Interest debt per share
05.745.4812.017.34
Market cap
320.67M320.67M320.67M602.28M333.92M
Enterprise value
0587.82M575.87M754.08M533.06M
P/E ratio
-1.61-0.99-2.32-2.18-1.31
Price to sales ratio
5.887.241.2911.053.65
POCF ratio
-2.19-1.54-4.73-2.91-1.41
PFCF ratio
-1.63-1.2-3.56-2.66-1.28
P/B Ratio
07.344.31.671.08
PTB ratio
07.344.31.671.08
EV to sales
013.272.3213.835.83
Enterprise value over EBITDA
0-1.82-5.08-2.41-2.12
EV to operating cash flow
0-2.83-8.49-3.64-2.25
EV to free cash flow
0-2.2-6.39-3.33-2.05
Earnings yield
-0.62-1.01-0.43-0.46-0.76
Free cash flow yield
-0.61-0.83-0.28-0.38-0.78
Debt to equity
03.061.710.780.87
Debt to assets
00.420.410.370.41
Net debt to EBITDA
0-0.83-2.25-0.48-0.79
Current ratio
00.20.332.963.77
Interest coverage
-13.1400030.88
Income quality
0.730.650.560.710.93
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
3.676.721.194.82.72
Intangibles to total assets
00.070.060.030.03
Capex to operating cash flow
0.350.290.330.090.1
Capex to revenue
-0.93-1.35-0.09-0.36-0.25
Capex to depreciation
-3.81-4.75-1.69-1.2-1.98
Stock based compensation to revenue
0.751.40.2510.45
Graham number
024.2120.6863.6437.39
ROIC
0-1.1-0.5-0.32-0.31
Return on tangible assets
0-1.11-0.47-0.37-0.4
Graham Net
0-17.14-12.62-7.62-1.61
Working capital
0-82.56M-50.76M193.18M221.09M
Tangible asset value
021.16M55.86M337.87M291.11M
Net current asset value
0-250.42M-212.89M-108.29M-45.32M
Invested capital
03.061.710.780.87
Average receivables
009.06M13.84M18.98M
Average payables
0013.77M6.59M6.62M
Average inventory
0063.8M6.74M-50.24M
Days sales outstanding
061.1915.73113.7783.61
Days payables outstanding
02.5K483.78174.67100.34
Days of inventory on hand
008.63K-3.31K189.86
Receivables turnover
05.9623.213.214.37
Payables turnover
00.150.752.093.64
Inventory turnover
000.04-0.111.92
ROE
0-7.4-1.85-0.77-0.82
Capex per share
-2.18-2.57-0.96-0.83-0.64

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.351.58K0.960.710.24
Net income per share
-1.75-649.41-0.98-0.83-1.4
Operating cash flow per share
-1.58-1.56K-1.13-0.64-0.42
Free cash flow per share
-1.93-1.65K-1.27-0.72-0.47
Cash per share
8.387.47K7.825.554.9
Book value per share
8.388.71K9.237.215.99
Tangible book value per share
7.878.17K8.796.845.85
Share holders equity per share
8.388.71K9.237.215.99
Interest debt per share
7.117.58K6.045.175.08
Market cap
561.24M333.92K443.37M515.78M200.62M
Enterprise value
707.5M199.47M516.7M683.36M370.55M
P/E ratio
-2.080-2.61-3.06-0.7
Price to sales ratio
41.860.0110.6514.3116.67
POCF ratio
-9.21-0.01-9.03-15.79-9.33
PFCF ratio
-7.55-0.01-8.04-14.08-8.27
P/B Ratio
1.7401.11.40.65
PTB ratio
1.7401.11.40.65
EV to sales
52.773.5512.4118.9630.79
Enterprise value over EBITDA
-10.74-8.05-10.48-14.97-10.98
EV to operating cash flow
-11.61-3.6-10.53-20.92-17.23
EV to free cash flow
-9.52-3.4-9.37-18.65-15.28
Earnings yield
-0.12-69.31-0.1-0.08-0.36
Free cash flow yield
-0.13-175.63-0.12-0.07-0.12
Debt to equity
0.850.870.670.720.85
Debt to assets
0.390.410.360.370.41
Net debt to EBITDA
-2.22-8.03-1.49-3.67-5.03
Current ratio
4.373.775.074.994.08
Interest coverage
-61.38-1.6K11.1800
Income quality
0.92.41.040.780.3
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
4.60.881.641.664.26
Intangibles to total assets
0.030.030.030.030.01
Capex to operating cash flow
0.220.060.120.120.13
Capex to revenue
-1-0.06-0.15-0.11-0.23
Capex to depreciation
-5.64-1.36-2.7-1.77-0.99
Stock based compensation to revenue
0.910.170.230.210.81
Graham number
18.1511.28K14.2511.5713.73
ROIC
-0.08-0.03-0.05-0.05-0.12
Return on tangible assets
-0.1-0.04-0.06-0.06-0.11
Graham Net
-1.39-1.8K0.21-0.87-1.35
Working capital
269.52M221.09M312.89M266.77M209.25M
Tangible asset value
303.65M291.11M382.14M348.49M299.65M
Net current asset value
-36.15M-45.32M48.7M-4.55M-57.13M
Invested capital
0.850.870.670.720.85
Average receivables
12.1M16.5M31.11M42.68M31.81M
Average payables
7.33M7.6M10.3M9.84M5.79M
Average inventory
00-20.63M-42.68M-22.05M
Days sales outstanding
80.833.5889.2110.1145.95
Days payables outstanding
1.91K42.33280.77125.0196.32
Days of inventory on hand
00-864.42-878.660
Receivables turnover
1.112.681.010.820.62
Payables turnover
0.052.130.320.720.93
Inventory turnover
00-0.1-0.10
ROE
-0.21-0.07-0.11-0.11-0.23
Capex per share
-0.35-88.84-0.14-0.08-0.05

TSVT Frequently Asked Questions

What is 2seventy bio, Inc. stock symbol ?

2seventy bio, Inc. is a US stock , located in Cambridge of Ma and trading under the symbol TSVT

Is 2seventy bio, Inc. buy or a sell ?

1 stock analysts have 1 predictions with a medium analyst target price of $26. The lowest prediction is $26 and the highest is $26

What is TSVT stock prediction ?

What is 2seventy bio, Inc. stock quote today ?

2seventy bio, Inc. stock price is $3.1 today.

Is 2seventy bio, Inc. stock public?

Yes, 2seventy bio, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Same Sector
Top Correlated Stocks
Similar Market Cap